The global medical devices market was valued at USD 572.31 billion in 2025 and is projected to grow from USD 604.99 billion in 2026 to USD 1,032.66 billion by 2034, exhibiting a CAGR of 6.90%.
That growth represents a complete transformation of how healthcare gets delivered, regulated, and commercialized across every market.
The medical device trends reshaping 2026 are fundamental shifts in technology, regulation, market access, and operational strategy. Companies that grasp these changes early gain a competitive advantage, and those that miss them risk obsolescence in markets moving faster than their compliance timelines.
AI has gone mainstream in medical devices. Here are five trends shaping the industry in 2026.
Trend 1. AI and Smart Devices Are Transforming Patient Care
In 2025, the FDA cleared 331 AI/ML-enabled medical devices. For context, that number was just 6 in 2015. The majority of the 1,430 AI-enabled devices ever approved landed in just the last three years. The pace isn’t slowing down.
What that looks like in practice is hospitals running AI diagnostic imaging that catches cancers that are otherwise missed and ECG devices flagging cardiac arrhythmias in real-time.
Radiology accounts 76% of all FDA-authorized AI/ML devices, but the wave is spreading fast. AI-powered decision support is everywhere now, from cardiology and neurology to diabetes management and surgical planning.
Companies that are embracing AI move faster, perform better, and stand out. Companies that treat it as optional are already falling behind.
Trend 2. Regulatory Standards Are Becoming Stricter and More Complex
The regulatory landscape is going through its biggest shake-up in decades, and it’s happening everywhere at once.
In the EU, manufacturers must register new MDR/IVDR devices in EUDAMED before placing them on the market from May 28, 2026, with legacy devices following by November 28, 2026.
The European Commission proposed simplifications to the rules on December 16, 2025, but those reforms still need legislative approval and aren’t expected until late 2026 or 2027 at the earliest.
In the US, the FDA is focused squarely on AI. In December 2024, it issued final guidance on Predetermined Change Control Plans (PCCPs) for AI-enabled device software functions. This lets manufacturers pre-specify how algorithms can be updated post-market without a full resubmission every time, which is practically a huge deal for AI devices that are designed to keep learning and improving.
For global manufacturers, the challenge only gets tougher. Different markets want different evidence, documentation, and even timelines. In fact, a device cleared in weeks in the US can face 18+ month delays in Europe due to Notified Body backlogs.
And that’s before you factor in language. Regulatory submissions need perfect accuracy across dozens of languages. IFUs must meet local language laws and cultural expectations. Software interfaces have to support multiple languages without creating usability issues that could put patients at risk.
This is where medical device translation services become paramount.
Trend 3. Connected Devices Are Expanding Remote and Personalized Care
The Remote Patient Monitoring market was worth $28.92 billion in 2024 and is on track to reach $138.4 billion by 2033, representing a 19% CAGR.
Chronic disease management no longer means constant hospital visits. Cardiac patients wear monitors that stream ECG data directly to their cardiologists, and diabetics get automatic alerts when glucose trends turn dangerous. Moreover, post-surgical patients recover at home while clinicians keep a close eye remotely.
In 2025, devices and software made up 56.14% of the RPM market. This included wearables, glucose meters, pulse oximeters, and ECG trackers, all of which were connected and feeding data.
The advantages of these are lower costs, better outcomes, and fewer readmissions. But connectivity brings new challenges, such as cybersecurity and ongoing software maintenance that traditional hardware manufacturers never had to consider.
This means that localization is all the more tough. It’s not just translating a label anymore; it’s adapting entire cloud platforms, mobile apps, and interfaces for different languages.
Trend 4. Emerging Markets Are Driving Global Growth Opportunities
The Asia Pacific medical devices market was valued at $127.62 billion in 2025 and is projected to hit $230.71 billion by 2034. In fact, India alone is growing at roughly 16.4% CAGR and is on track to reach roughly $50 billion by 2030.
That’s nearly triple the global average.
China, India, Southeast Asia, and Latin America each come with its own set of challenges. Different health problems, price sensitivities, infrastructure realities, regulatory frameworks, and distribution channels. You simply can’t drop a product into these markets and expect it to work.
Winning here requires local partnerships, culturally adapted product strategies, and localization that goes well beyond basic translation. A mistranslated document in this process can quite literally mean a full resubmission from scratch.
Trend 5. Sustainability Is Becoming a Key Priority in Medical Technology
Sustainability isn’t a buzzword. It spans the entire product lifecycle. Your design choices determine recyclability, the manufacturing processes impact carbon footprint, and packaging materials affect waste generation.
45% of medical device manufacturers have now integrated sustainability into their corporate strategies, and the global sustainable medical devices market is expected to reach $15 billion by 2028. This is a major leap since healthcare accounts for roughly 4.4% of global carbon emissions!
The good news is that companies are already making meaningful progress. For example, Coloplast achieved 77% production waste recycling and cut Scope 1 and 2 emissions by 27%.
More than 60% of new devices are now designed with end-of-life recyclability in mind, and the use of biodegradable plastics in medical devices has jumped 22% over the last three years.
What Does This Mean for Your Global Strategy?
AI, tighter regulations, connected devices, emerging market growth, and sustainability all of these trends have one thing in common. And that is, they demand seamless multilingual communication at every level.
A translation error in a regulatory submission costs months and millions. A poorly localized device interface frustrates users, and that means they’re not coming back.
At the end of the day, an emerging market strategy without cultural depth wastes time and budget.
At EC Innovations, we provide medical device translation services that bring regulatory expertise, medical terminology, and cultural intelligence to the table. This allows you, as manufacturers, to move confidently into every market you target.
From regulatory documentation and multilingual labeling to localization and translation, we make sure every communication supports your global strategy, keeps you compliant, and lands with local stakeholders.
Get in touch to find out how professional localization can speed up your market entry, reduce regulatory risk, and help you make the most of these trends.
Your new innovation deserves to be seen. We can make that happen.
